Topical ENS-002 for Eczema
(EnSync Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.
Will I have to stop taking my current medications?
The trial requires participants to stop certain medications before starting ENS-002. For example, you must stop systemic corticosteroids 28 days before, and topical high-potency corticosteroids 28 days before. However, if you're on a stable dose of certain medications like oral or topical H1 antihistamines, you can continue them during the study.
Who Is on the Research Team?
Bernardo Cervantes, PhD
Principal Investigator
Concerto Biosciences
Are You a Good Fit for This Trial?
This trial is for adults with atopic dermatitis, commonly known as eczema. Participants should have a diagnosis of this skin condition to qualify.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ENS-002 lotion applied topically once or twice daily depending on cohort for up to 14 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ENS-002
Find a Clinic Near You
Who Is Running the Clinical Trial?
Concerto Biosciences
Lead Sponsor